{"url_path":"/sec/tenx/8-k/2026-06-30/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/34956/0001193125-26-290661-index.html","accession_number":"0001193125-26-290661","cik":"0000034956","ticker":"TENX","issuer_name":"TENAX THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/34956/0001193125-26-290661-index.html","primary_entity_key":"0000034956","primary_entity_name":"TENAX THERAPEUTICS, INC."},"word_count":128,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit 10.1*\n  \n[Sixth Amendment to the License Agreement, dated June 29, 2026, between Tenax Therapeutics, Inc. and Orion Corporation.](d117070dex101.htm)\n\nExhibit 104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n*\n\nCertain schedules, exhibits and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish a copy of any omitted schedules to the Securities and Exchange Commission upon request.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nTENAX THERAPEUTICS, INC.\n\nDate: June 30, 2026\n\nBy:\n \n\n/s/ Christopher T. Giordano\n\nName:\n \nChristopher T. Giordano\n\nTitle:\n \nPresident and Chief Executive Officer"}